drugset / Trial / NCT03530397
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
Timeline
- Start
- 2018-04-24
- Primary completion
- 2025-07-14
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Volrustomig | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |
Indications
No indication recorded.